Myriad Genetics (NASDAQ:MYGN) Stock Price Target Raised at Leerink Partners

Myriad Genetics (NASDAQ:MYGN) had its price target lifted by Leerink Partners from $5.00 to $8.00 in a research note published on Thursday,Benzinga reports. The firm currently has a market perform rating on the stock.

Several other equities analysts also recently weighed in on the stock. Craig Hallum raised their target price on shares of Myriad Genetics from $4.00 to $8.00 and gave the company a “buy” rating in a report on Friday, October 2nd. Stephens lowered their target price on shares of Myriad Genetics from $5.00 to $3.00 and set an “equal weight” rating for the company in a report on Tuesday, August 18th. Weiss Ratings downgraded Myriad Genetics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, October 27th. TD Cowen increased their price target on Myriad Genetics from $4.00 to $4.50 and gave the company a “hold” rating in a report on Tuesday, October 13th. Finally, Wall Street Zen cut shares of Myriad Genetics from a “hold” rating to a “sell” rating in a research report on Saturday, August 8th. One investment analyst has rated the stock with a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $5.55.

Myriad Genetics Stock Up 4.5%

MYGN opened at $6.29 on Thursday. The company has a debt-to-equity ratio of 0.40, a current ratio of 2.21 and a quick ratio of 1.98. Myriad Genetics has a 12 month low of $2.74 and a 12 month high of $8.09. The stock has a market capitalization of $601.64 million, a P/E ratio of -4.62 and a beta of 1.62. The business has a 50 day simple moving average of $4.45 and a 200-day simple moving average of $4.62.

Myriad Genetics (NASDAQ:MYGN) last released its earnings results on Wednesday, November 4th. The company reported ($0.11) EPS for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.09. Myriad Genetics had a negative return on equity of 18.88% and a negative net margin of 16.07%. The company had revenue of $202.70 million during the quarter, compared to the consensus estimate of $191.33 million. On average, equities analysts anticipate that Myriad Genetics will post -0.99 earnings per share for the current fiscal year.

Institutional Trading of Myriad Genetics

Several large investors have recently added to or reduced their stakes in MYGN. Orbimed Advisors LLC acquired a new position in shares of Myriad Genetics during the first quarter valued at $562,500,000. BlackRock Inc. bought a new stake in shares of Myriad Genetics in the 2nd quarter worth $62,184,000. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in shares of Myriad Genetics in the second quarter valued at $8,039,000. Man Group plc bought a new position in Myriad Genetics during the second quarter valued at about $5,189,000. Finally, Bank of America Corp DE acquired a new position in Myriad Genetics during the second quarter worth about $5,150,000. 99.02% of the stock is currently owned by institutional investors and hedge funds.

Myriad Genetics News Roundup

Here are the key news stories impacting Myriad Genetics this week:

• Positive Sentiment: Third-quarter revenue was $202.7 million, above the $191.3 million consensus estimate, while the loss of $0.11 per share was narrower than analysts’ expected $0.20 loss. Revenue rose 6% sequentially, supported by improved product mix and higher average revenue per test. Myriad Genetics Q3 2026 results and outlook
• Positive Sentiment: Myriad raised the midpoint of its full-year 2026 revenue guidance, outlining a $780 million–$790 million outlook following its agreement to sell its Prenatal Health business for $210 million. The company said the transaction will support strategic growth initiatives. Myriad revenue outlook and divestiture
• Neutral Sentiment: TD Cowen raised its price target to $6.75 from $4.50, retaining a Hold rating. Leerink Partners lifted its target to $8 from $5, while keeping a Market Perform rating. The higher targets reflect improved estimates, but both firms maintained non-buy ratings. TD Cowen rating Leerink Partners rating
• Negative Sentiment: Myriad disclosed that it detected unauthorized access to its information technology systems on November 2 and is investigating whether data was accessed. The potential exposure and any operational or regulatory consequences remain unclear. Cybersecurity incident report

About Myriad Genetics

Myriad Genetics, Inc is a molecular diagnostics company that develops and provides genetic tests and related services to help healthcare providers assess disease risk, guide treatment decisions and support patient care. The company’s testing portfolio spans hereditary cancer, precision oncology, women’s health, mental health and other clinical applications.

Its products include hereditary cancer risk tests such as MyRisk and BRACAnalysis, which evaluate inherited genetic variants associated with cancers including breast and ovarian cancer.